PGCR 82.5mg Extended Release Tablet 10pcs

Uses of PGCR 82.5mg Extended Release Tablet

• Treatment of Neuropathic pain
• Treatment of Fibromyalgia
• Treatment of Epilepsy/Seizures

How does PGCR 82.5mg Extended Release Tablet work?

PGCR 82.5mg Extended Release Tablet works by reducing the release of a chemical (neurotransmitter) in the brain responsible for the sensation of pain.

Side Effects of PGCR 82.5mg Extended Release Tablet

Common side effects in adults include dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and difficulty with concentration. In pediatric patients, increased weight and appetite are the most common side effects of partial-onset seizure treatment.

Quick Suggestions:

• PGCR 82.5 should be taken as per the dose and duration prescribed by your doctor.
• It may cause sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
• It may cause blurring or loss of vision. Inform your doctor immediately if you notice any vision changes.
• Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior.
• Do not stop taking the medication suddenly without talking to your doctor as it may worsen your underlying condition.

Dosage of PGCR 82.5mg Extended Release Tablet

• Neuropathic Pain (DPN) in Adults: Start with 50 mg three times daily (150 mg/day), increasing to 300 mg/day within a week if tolerated. The maximum dose is 100 mg three times daily (300 mg/day). For Pregabalin CR capsules, begin at 165 mg once daily, increasing to 330 mg once daily if tolerated, with a maximum of 330 mg/day.
• Postherpetic Neuralgia (PHN) in Adults: Start with 75-150 mg twice daily or 50-100 mg three times daily (150-300 mg/day). Increase to 300 mg/day within a week if tolerated. The maximum dose can be increased to 600 mg/day for those who tolerate it but do not find relief at lower doses. For Pregabalin CR, start at 165 mg once daily, increasing to a maximum of 660 mg/day if needed.
• Fibromyalgia in Adults: Start with 75 mg twice daily (150 mg/day), increasing to 300 mg/day within a week if tolerated. The maximum dose is 450 mg/day.
• Neuropathic Pain from Spinal Cord Injury in Adults: Start with 75 mg twice daily (150 mg/day), increasing to 300 mg/day within a week if tolerated. The maximum dose is 600 mg/day.
• Conversion from Pregabalin Capsules to Pregabalin CR: On the day of conversion, take the morning dose of Pregabalin capsules and switch to Pregabalin CR after an evening meal.

Pharmacology

Pregabalin is a structural derivative of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. However, Pregabalin does not directly bind to GABA receptors. Instead, it binds with high affinity to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, which is thought to contribute to its anti-nociceptive and antiseizure effects.

Administration of PGCR 82.5mg Extended Release Tablet

Overdose symptoms include reduced consciousness, confusion, agitation, seizures, and heart block. Supportive care is recommended, as there is no specific antidote. Elimination of unabsorbed drugs can be attempted by emesis or gastric lavage.

Pregabalin is taken orally, with or without food. Pregabalin CR tablets should be taken after an evening meal and swallowed whole without splitting, crushing, or chewing. If a dose is missed after an evening meal, it should be taken before bedtime following a snack. If missed before bedtime, take it after a morning meal. Gradual tapering is recommended when discontinuing Pregabalin.

Children and Adolescents: Safety and effectiveness have not been established for certain conditions in pediatric patients. For partial-onset seizures, it is not established for those below 1 month of age.

Interaction

• Drug Interactions: PG CR is unlikely to have significant pharmacokinetic drug interactions.
• Food and Other Interactions: Not applicable.

Contraindications

Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin or any of its components.

Pregnancy & Lactation

There are no adequate studies on the use of Pregabalin in pregnant women, and small amounts of the drug have been found in breast milk. Due to the potential risk of tumorigenicity, breastfeeding is not recommended during treatment.

Precautions & Warnings

• Angioedema: Discontinue immediately if symptoms occur, as it may lead to life-threatening respiratory issues.
• Hypersensitivity Reactions: Discontinue immediately if symptoms like hives or wheezing occur.
• Suicidal Risk: PG CR may increase the risk of suicidal thoughts or behavior.
• Respiratory Depression: Use cautiously in patients with respiratory impairment or when taken with CNS depressants.
• Dizziness and Somnolence: May impair the ability to drive or operate machinery.
• Discontinuation: Taper off gradually over at least one week.
• Peripheral Edema: Use cautiously with thiazolidinedione antidiabetic agents.

Storage:

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.